Enrollment Initiated in Second Phase III Clinical Study for Ivonescimab, HARMONi-3
Continuing Enrollment of HARMONi Phase III Study, with Enrollment Completion Expected in Second Half of.
Reports Third-Quarter Diluted EPS of $1.00 on a GAAP Basis, a Decrease of 54.8 Percent; Adjusted Diluted EPS of $2.95, a Decrease of 19.4 Percent; These.
Mr. Soni Invests $5 Million in Summit while Joining Executive Team
In Corresponding Appointments, Dave Gancarz, Urte Gayko, PhD, Fong Clow, DSc, & Allen S. Yang, MD, PhD, Elevated to Newly.
Summit Therapeutics (SMMT) Appoints Leader Manmeet S. Soni as COO streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
– Former FDA Associate Commissioner of External Affairs brings nearly 20 years of communications, patient advocacy and public affairs experience across government, public and private sectors –MENLO PARK, Calif. (BUSINESS WIRE) ReCode Therapeutics, a clinical-stage genetic medicines company using superior delivery.